Cinical effect and prognosis of lyophilized recombinant human brain natriuretic peptide at different times for acute left heart failure
10.3760/cma.j.issn.1673-4904.2015.07.013
- VernacularTitle:冻干重组人脑利钠肽的用药时机对急性左心衰竭患者临床效果和预后的研究
- Author:
Jinhong XIE
;
Huaimin GUAN
- Publication Type:Journal Article
- Keywords:
Lyophilized recombinant human brain natriuretic peptide;
Heart failure;
Ventricular function
- From:
Chinese Journal of Postgraduates of Medicine
2015;38(7):513-516
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical effect and prognosis of lyophilized recombinant human brain natriuretic peptide at different times for acute left heart failure.Methods A total of 58 consecutive patients diagnosed as acute left heart failure from February 2013 to February 2014 were randomly divided into early group (30 patients) and late group (28 patients).The patients in early group received lyophilized recombinant human brain natriuretic peptide and other common treatment immediately after arriving at hospital,and the patients in late group received lyophilized recombinant human brain natriuretic peptide until symptoms were hard to control.Results After treatment,the NYHA class and the levels of brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) in early group and late group were significant differences:(1.4 ± 0.5) grade vs.(2.6 ± 0.7) grade,(934.2 ± 52.4) ng/L vs.(1 632.5 ± 147.6) ng/L,(49.6 ± 5.4)％ vs.(31.2 ± 6.7)％,P ＜ 0.01 or ＜ 0.05.The average stay and expenses in early group were significandy less than those in control group:(11.2 ± 3.4) d vs.(19.7 ± 4.2) d,(15.8 ± 4.6) thousand Yuan vs.(27.4 ± 6.3) thousand Yuan,P ＜ 0.05.The total effective rate and survival rate in early group were significantly higher than those in late group:66.7％(20/30) vs.39.3％(11/28),P ＜ 0.05.Conclusion Earlier application of lyophilized recombinant human brain natriuretic can significantly improve the symptoms in acute left heart failure patients.
